08 August 2022: Clinical Research
Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
Beatriz Barranco-Fragoso 12ABC , Shreya C. Pal 34CDEFG , Luis E. Díaz-Orozco 34ABCDEF , Rita Dorantes-Heredia 5BCD , Xingshun Qi 6F , Nahum Méndez-Sánchez 34ACDEF*DOI: 10.12659/MSM.937528
Med Sci Monit 2022; 28:e937528
Table 2 Participant information database-main characteristics:The main characteristics of the patients enrolled in the study are presented below, with most being composed of women, morbidly obese individuals, and variable CD11c+ cell expression.
| Patients with MAFLD (n=128)Mean age: 44.9 (±12.5) | (N) | (%) |
|---|---|---|
| Men | 48 | 37.50 |
| Women | 80 | 62.50 |
| Non-obese ( | 19 | 14.84 |
| Obesity grade I–II (≥30–39.9 kg/m) | 33 | 25.78 |
| Morbid obesity (≥40 kg/m) | 76 | 59.38 |
| Fibrosis | 64 | 50.00 |
| Non-fibrosis | 64 | 50.00 |
| Hepatic dendritic cells’ expression (CD11c) | 72 | 56.25 |
| No expression of Hepatic dendritic cells (CD11c) | 56 | 43.75 |
| MAFLD – metabolic (dysfunction)-associated fatty liver disease; T2DM – type 2 diabetes mellitus. | ||